Feruglio G A
G Ital Cardiol. 1978;8 Suppl 1:1-7.
The current status of cardiac pacing in Italy is outlined by the following figures: 121 hospitals implant over 10,000 pacemakers each year. Of this number 69% are new implants which raises the incidence of new treated cases to 111 per million population, with the highest peach (197) in Tuscany. This figure was only 61 in 1973. At elsewhere, the dominant age group is the 7th decade; the prime indication for pacing is the symptomatic patient with a-v block (62% of all cases), the next most common one being chronic fascicular block (11%) and sick sinus syndrome (10%). The transvenous route is utilized in 98.3% of cases. The pacemaker of choice is the R-inhibited units; fixed rate units are used in only 4% of cases and units with conventional mercury battery cells in 66%, in favour of pacers with longer energy sources (e.g. lithium). Fifteen companies are supplying pacemakers in Italy and four of them are local manufacturers. An estimate 18,000 patients are being paced throughout the country to-day. Their density is highest in the region Friuli-Venezia Giulia (948 per million population). Follow-up of patients as a whole is not satisfactory being adequate only in about 50% of hospitals; telephone monitoring is available but in a few locations. The average cost of permanent pacing in Italy is the equivalent of 2.50 U.S. dollars per day.
每年有121家医院植入超过10000台起搏器。其中69%为新植入,这使得新治疗病例的发病率升至每百万人口111例,托斯卡纳地区发病率最高(197例)。1973年这一数字仅为61例。在其他地方,主要年龄组为70多岁;起搏的主要指征是有症状的房室传导阻滞患者(占所有病例的62%),其次最常见的是慢性束支传导阻滞(11%)和病态窦房结综合征(10%)。98.3%的病例采用经静脉途径。首选的起搏器是R抑制型;仅4%的病例使用固定频率型,66%的病例使用传统汞电池型,更倾向于使用能量来源更长的起搏器(如锂)。意大利有15家公司供应起搏器,其中4家是本地制造商。据估计,目前全国有18000名患者正在接受起搏治疗。弗留利-威尼斯朱利亚地区的患者密度最高(每百万人口948例)。总体而言,患者随访情况并不理想,只有约50%的医院随访充分;电话监测虽有,但仅在少数地方可用。意大利永久性起搏的平均费用相当于每天2.50美元。